Please login to the form below

Not currently logged in
Email:
Password:

cell and gene therapy

This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.

Syncona start-up Quell Therapeutics appoints chief exec

Syncona start-up Quell Therapeutics appoints chief exec

Syncona is on a roll at present, having launched a string of new cell and gene therapy-focused companies in the last few years. ... He has 25 years’ experience in the industry, including solid organ and cell transplantation therapy areas.

Latest news

More from news
Approximately 38 fully matching, plus 38 partially matching documents found.

Latest Intelligence

  • Gene therapy market access Q&A Gene therapy market access Q&A

    Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy Catapult gives his personal view on how to get the new therapies to patients. ... Jesper Jorgensen, Health Economics and Market Access Manager, Cell and Gene Therapy

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    All this points to a revolution brought about by cell and gene therapy, not just in clinical care, but also in the pricing and reimbursement framework to support it. ... He’s seen a rapid change in attitudes towards healthcare systems in the last 12

  • Cell and gene therapy Cell and gene therapy

    Lonza has worked with 150 cell and gene therapy developers and each project has required a different approach, Hong added. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said Hong.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... Novartis has a deal with Spark to market Luxturna in Europe,

  • The handover: Pfizer reshapes itself for a new era The handover: Pfizer reshapes itself for a new era

    Pfizer also has a considerable stake in one of the most exciting emerging areas of innovation, cell and gene therapy. ... It has gene therapy deals with Spark in haemophilia and with Sangamo in ALS.

More from intelligence
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest appointments

  • Health comms agency emotive hires new cell and gene therapy leader Health comms agency emotive hires new cell and gene therapy leader

    Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where

  • Weekly industry appointments Weekly industry appointments

    GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and

  • Avita Medical appoints CEO Avita Medical appoints CEO

    chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene

More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era

    the cost curve to accommodate new and expensive cell and gene therapies.  In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.

  • Event: World Pharma Pricing and Market Access Congress

    Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March. ... A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding

  • OPEN Health

    With over 500 staff globally and 4 key practice areas:. OPEN Health - Medical Communications. ... OPEN Health Medical Communications announces Group MD promotions and welcomes new Creative Director.

  • Random42 attending Biotech Showcase in San Francisco

    Alzheimer’s Disease. Cell and Gene Therapy. Immuno-Oncology. NASH (Nonalcoholic steatohepatitis). Rare and Orphan Diseases. ... Random42 produce over 200 individual digital projects each year and have won over 175 industry awards in their 26-year

  • Training the next generation of biotech leaders

    As a result, he is at the forefront of inspiring the next generation of scientists to make breakthroughs in cell and gene therapy. ... It brings engineers and people from the life sciences sector into the department to learn about biochemical engineering

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics